ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 155 filers reported holding ASCENDIS PHARMA A/S in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $11,828,000 | +54.9% | 76,643 | +48.4% | 0.09% | +33.3% |
| Q2 2020 | $7,638,000 | +115.7% | 51,643 | +64.2% | 0.07% | +73.7% |
| Q1 2020 | $3,541,000 | -49.1% | 31,443 | -37.1% | 0.04% | -37.7% |
| Q4 2019 | $6,956,000 | +188.9% | 50,000 | +100.0% | 0.06% | +177.3% |
| Q3 2019 | $2,408,000 | -16.4% | 25,000 | 0.0% | 0.02% | -12.0% |
| Q2 2019 | $2,879,000 | -18.7% | 25,000 | -50.0% | 0.02% | -16.7% |
| Q3 2018 | $3,543,000 | +6.5% | 50,000 | 0.0% | 0.03% | +50.0% |
| Q2 2018 | $3,326,000 | +1.7% | 50,000 | 0.0% | 0.02% | -39.4% |
| Q1 2018 | $3,270,000 | +8.8% | 50,000 | -33.3% | 0.03% | +6.5% |
| Q4 2017 | $3,005,000 | – | 75,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |